Dr. Jan Freijer's current address is Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. At the time the analysis was performed he was an employee of Astellas Pharma Europe.
Editor's Choice: Pediatric Pharmacology
Predicting the “First dose in children” of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages
Version of Record online: 28 MAR 2014
© 2014, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 54, Issue 9, pages 1006–1015, September 2014
How to Cite
Strougo, A., Yassen, A., Monnereau, C., Danhof, M. and Freijer, J. (2014), Predicting the “First dose in children” of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. Journal of Clinical Pharma, 54: 1006–1015. doi: 10.1002/jcph.294
- Issue online: 5 AUG 2014
- Version of Record online: 28 MAR 2014
- Manuscript Accepted: 21 MAR 2014
- Manuscript Received: 7 JAN 2014
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Table S1. Observed Data in Adults Used for Scaling to Children
Table S2. Observed Data in Children and Percentage Error in Relation to the Predicted Clearance When Using Scaling Approaches in Combination With Different Maturation Functions for the CYP3A Activity in the Liver
Table S3. List of References Included in the Database
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.